PL2444085T3 - Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka - Google Patents

Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka

Info

Publication number
PL2444085T3
PL2444085T3 PL11184401T PL11184401T PL2444085T3 PL 2444085 T3 PL2444085 T3 PL 2444085T3 PL 11184401 T PL11184401 T PL 11184401T PL 11184401 T PL11184401 T PL 11184401T PL 2444085 T3 PL2444085 T3 PL 2444085T3
Authority
PL
Poland
Prior art keywords
treatment
cancer
receptor antagonists
androgen receptor
diarylhydantoin compounds
Prior art date
Application number
PL11184401T
Other languages
English (en)
Polish (pl)
Inventor
Charles L Sawyers
Michael E Jung
Charlie D Chen
Samedy Ouk
Derek Welsbie
Chris Tran
John Wongpivat
Dongwon Yoo
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37431537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2444085(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of PL2444085T3 publication Critical patent/PL2444085T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compounds Of Unknown Constitution (AREA)
PL11184401T 2005-05-13 2006-03-29 Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka PL2444085T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68083505P 2005-05-13 2005-05-13
US75035105P 2005-12-15 2005-12-15
US75655206P 2006-01-06 2006-01-06
EP11184401.5A EP2444085B1 (en) 2005-05-13 2006-03-29 Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
EP06748863.5A EP1893196B2 (en) 2005-05-13 2006-03-29 Diarylhydantoin compound

Publications (1)

Publication Number Publication Date
PL2444085T3 true PL2444085T3 (pl) 2015-07-31

Family

ID=37431537

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11184401T PL2444085T3 (pl) 2005-05-13 2006-03-29 Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka
PL06748863T PL1893196T5 (pl) 2005-05-13 2006-03-29 Związek diarylohydantoinowy

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06748863T PL1893196T5 (pl) 2005-05-13 2006-03-29 Związek diarylohydantoinowy

Country Status (29)

Country Link
EP (5) EP2561871A1 (cg-RX-API-DMAC7.html)
JP (13) JP4644737B2 (cg-RX-API-DMAC7.html)
KR (12) KR102481886B1 (cg-RX-API-DMAC7.html)
CN (6) CN120682155A (cg-RX-API-DMAC7.html)
AT (1) ATE541571T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006248109B2 (cg-RX-API-DMAC7.html)
BE (1) BE2013C074I2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0610359B8 (cg-RX-API-DMAC7.html)
CA (1) CA2608436C (cg-RX-API-DMAC7.html)
CY (2) CY1112798T1 (cg-RX-API-DMAC7.html)
DK (2) DK2444085T3 (cg-RX-API-DMAC7.html)
ES (2) ES2535179T3 (cg-RX-API-DMAC7.html)
HK (1) HK1217103A1 (cg-RX-API-DMAC7.html)
HR (2) HRP20120323T4 (cg-RX-API-DMAC7.html)
HU (1) HUS1300076I1 (cg-RX-API-DMAC7.html)
IL (4) IL187328A (cg-RX-API-DMAC7.html)
LU (1) LU92338I2 (cg-RX-API-DMAC7.html)
ME (1) ME01992B (cg-RX-API-DMAC7.html)
MX (4) MX394667B (cg-RX-API-DMAC7.html)
NO (4) NO339997B1 (cg-RX-API-DMAC7.html)
NZ (3) NZ564223A (cg-RX-API-DMAC7.html)
PL (2) PL2444085T3 (cg-RX-API-DMAC7.html)
PT (2) PT1893196E (cg-RX-API-DMAC7.html)
RS (2) RS53967B1 (cg-RX-API-DMAC7.html)
RU (3) RU2448096C3 (cg-RX-API-DMAC7.html)
SG (1) SG10201703816SA (cg-RX-API-DMAC7.html)
SI (2) SI1893196T2 (cg-RX-API-DMAC7.html)
WO (1) WO2006124118A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA200710870B (cg-RX-API-DMAC7.html)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2550447A1 (en) 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
AU2005232526B2 (en) 2004-02-24 2011-06-23 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
KR102481886B1 (ko) * 2005-05-13 2022-12-28 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
LT2656842T (lt) 2006-03-27 2016-09-26 The Regents Of The University Of California Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui
CN102755318B (zh) * 2006-03-29 2014-09-10 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
TW200846338A (en) * 2007-02-01 2008-12-01 Chugai Pharmaceutical Co Ltd Pyridyl imidazolidine derivative having sulfamoyl group, and pharmaceutical use thereof
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
PE20121470A1 (es) * 2007-10-26 2012-11-18 Univ California Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
BRPI1007990A2 (pt) * 2009-02-24 2015-09-01 Medivation Prostate Therapeutics Inc Compostos específicos de diaril-hidantoína e diariltioidantoína.
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
EP2430190B1 (en) * 2009-05-12 2018-11-21 Koninklijke Philips N.V. Phosphodiesterase 4d7 as marker for malignant, hormone-sensitive prostate cancer
JP5659232B2 (ja) * 2009-09-10 2015-01-28 トン、ヨウヂ アンドロゲン受容体アンタゴニストおよびその使用
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
CA2773615A1 (en) 2009-09-11 2011-03-17 Arwed Cleve Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
ES2575215T3 (es) 2009-12-11 2016-06-27 Autifony Therapeutics Limited Derivados de imidazolidindiona
KR101819199B1 (ko) 2010-02-16 2018-01-16 아라곤 파마슈티컬스, 인코포레이티드 안드로겐 수용체 조절제 및 이의 용도
RU2554081C2 (ru) * 2010-02-24 2015-06-27 Медивэйшн Простейт Терапьютикс, Инк. Способ синтеза соединений диарилтиогидантоина и диарилгидантоина
RU2434851C1 (ru) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
WO2012076877A1 (en) 2010-12-06 2012-06-14 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
WO2012119559A1 (en) 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
WO2012143599A1 (en) 2011-04-21 2012-10-26 Orion Corporation Androgen receptor modulating carboxamides
CN103596943B (zh) 2011-06-07 2016-10-12 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
CN103997894B (zh) * 2011-07-29 2016-08-24 麦迪韦逊前列腺治疗股份有限公司 乳癌的治疗
SMT201900708T1 (it) 2011-11-30 2020-01-14 Astrazeneca Ab Trattamento di combinazione di un cancro
CN103159680A (zh) * 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
US9669030B2 (en) 2012-05-22 2017-06-06 Autifony Therapeutics Limited Hydantoin derivatives as Kv3 inhibitors
BR112014028991A2 (pt) 2012-05-22 2017-06-27 Autifony Therapeutics Ltd triazóis como inibidores de kv3
PT2894151T (pt) * 2012-09-04 2020-12-07 Shanghai hengrui pharmaceutical co ltd Derivados de imidazolina, seus métodos de preparação e suas aplicações em medicina
AU2013316754A1 (en) * 2012-09-11 2015-04-30 Dr. Reddy's Laboratories Limited Enzalutamide polymorphic forms and its preparation
CN105358535B (zh) * 2012-09-11 2019-01-04 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
WO2014062852A2 (en) * 2012-10-16 2014-04-24 Whitehead Institute For Biomedical Research Thiohydantoin derivatives and uses thereof
CA2889756C (en) 2012-10-26 2023-03-14 Memorial Sloan-Kettering Cancer Center Thiohydantoin compounds as androgen receptor modulators
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
RU2520134C1 (ru) * 2013-02-27 2014-06-20 Общество с ограниченной ответственностью "Авионко" (ООО "Авионко") Замещенные (r)-3-(4-метилкарбамоил-3-фторфениламино)-тетрагидро-фуран-3-енкарбоновые кислоты и их эфиры, способ их получения и применения
WO2014167428A2 (en) * 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
ES2712211T3 (es) 2013-06-20 2019-05-09 Bayer Cropscience Ag Derivados de arilsulfuro y arilsulfóxido acaricidas e insecticidas
WO2015018356A1 (zh) * 2013-08-08 2015-02-12 上海医药集团股份有限公司 二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
EP3046556A4 (en) * 2013-09-19 2017-04-26 Glaxosmithkline LLC Combination drug therapy
WO2015054804A1 (zh) * 2013-10-14 2015-04-23 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
EP3063135A1 (en) 2013-10-31 2016-09-07 Sun Pharmaceutical Industries Ltd Process for the preparation of enzalutamide
EP3083568A1 (en) 2013-12-16 2016-10-26 Sun Pharmaceutical Industries Ltd Processes and intermediates for the preparation of enzalutamide
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
EP3105208A1 (en) 2014-02-13 2016-12-21 Ranbaxy Laboratories Limited Process for the preparation of enzalutamide
CZ2014232A3 (cs) 2014-04-07 2015-10-14 Zentiva, K.S. Způsob výroby enzalutamidu
CN103896847B (zh) * 2014-04-09 2016-01-20 沈江 一种非甾体类抗雄激素化合物及其制备方法和应用
CN103910679B (zh) * 2014-04-23 2016-05-25 杭州新博思生物医药有限公司 一种恩杂鲁胺的制备方法
CN104003939B (zh) * 2014-06-06 2017-07-07 山东大学 二芳基取代乙内酰硫脲类化合物及其制备方法与应用
CN104016924B (zh) * 2014-06-16 2016-04-13 上海鼎雅药物化学科技有限公司 一种“一锅法”合成恩杂鲁胺的方法
WO2015196144A2 (en) 2014-06-20 2015-12-23 England Pamela M Androgen receptor antagonists
RU2557235C1 (ru) * 2014-07-08 2015-07-20 Александр Васильевич Иващенко Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
US20170190670A1 (en) * 2014-07-11 2017-07-06 Shilpa Medicare Limited Improved process for the preparation of enzalutamide
KR20200141533A (ko) 2014-12-05 2020-12-18 아라곤 파마슈티컬스, 인코포레이티드 항암 조성물
AU2015360767A1 (en) 2014-12-12 2017-06-08 Medivation Prostate Therapeutics Llc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
CN104610111A (zh) * 2014-12-26 2015-05-13 杭州和泽医药科技有限公司 一种4-异硫代氰酰基-2-(三氟甲基)苯甲腈的制备方法
CN105523958B (zh) * 2015-01-13 2017-11-03 北京海步医药科技股份有限公司 一种制备二芳基硫代乙内酰脲衍生物关键中间体的方法
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
AU2016209349B2 (en) * 2015-01-20 2020-05-07 Arvinas, Inc. Compounds and methods for the targeted degradation of the Androgen Receptor
CN106187905B (zh) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 丁鲁他胺的结晶形式及其制备方法
ITUB20151204A1 (it) 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
ITUB20151311A1 (it) * 2015-05-28 2016-11-28 Olon Spa Procedimento per la preparazione di enzalutamide
ITUB20151256A1 (it) 2015-05-28 2016-11-28 Olon Spa Processo industriale per la preparazione di enzalutamide
PT3305770T (pt) 2015-05-29 2023-04-26 Astellas Pharma Inc Processo para a produção de forma cristalina de enzalutamida
DK3348546T3 (da) 2015-09-10 2020-07-06 Jiangsu Hengrui Medicine Co Krystallinsk form af androgenreceptorinhibitor og fremgangsmåde til fremstilling deraf
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN110167556A (zh) * 2016-07-08 2019-08-23 詹森药业有限公司 用于治疗癌症的硫代乙内酰脲雄性激素受体拮抗剂
DK3527210T3 (da) 2016-12-16 2021-08-09 Kangpu Biopharmaceuticals Inc Kombineret sammensætning omfattende en benzoheterocyklisk forbindelse og en androgenreceptorvejsmodulator samt anvendelser deraf
EP3616696B1 (en) 2017-04-28 2025-03-05 Astellas Pharma Inc. Orally administrable enzalutamide-containing pharmaceutical composition
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
US10513504B2 (en) 2018-03-08 2019-12-24 Apotex Inc. Processes for the preparation of apalutamide and intermediates thereof
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
CN108976171B (zh) 2018-08-27 2020-06-16 长沙泽达医药科技有限公司 化合物、组合物及其在药物制备中的用途
JP2022509917A (ja) 2018-11-05 2022-01-25 ファイザー・インク がんを処置するための組合せ
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020113088A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
CN109796437B (zh) * 2019-02-26 2021-08-24 上海健康医学院 具有ar和hdac双重抑制作用的乙内酰脲类和乙内酰硫脲类化合物及用途
WO2020260469A1 (en) 2019-06-27 2020-12-30 Synthon B.V. Process for preparation of enzalutamide
CN110452166A (zh) * 2019-09-06 2019-11-15 浙江朗华制药有限公司 一种5-异硫氰酰基-3-三氟甲基-2-氰基吡啶的制备方法
CA3152909A1 (en) 2019-10-03 2021-04-08 Synthon Bv Pharmaceutical composition comprising enzalutamide
WO2021240206A1 (en) 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
BR112023002295A2 (pt) 2020-08-13 2023-03-14 Pfizer Terapia de combinação
CR20230306A (es) 2020-12-11 2023-09-01 Ildong Pharmaceutical Co Ltd Nuevos compuestos como inhibidor dual del receptor de andrógenos y de la fosfodiesterasa
AU2022244439A1 (en) 2021-03-24 2023-09-28 Astellas Pharma Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
EP4112603A1 (en) 2021-06-29 2023-01-04 Química Sintética, S.A. Processes for the preparation of non-steroidal antiandrogens
KR102861133B1 (ko) 2021-10-13 2025-09-16 주식회사 엘지에너지솔루션 배터리 충방전 프로파일 분석 방법 및 배터리 충방전 프로파일 분석 장치
CN114181155A (zh) * 2021-12-21 2022-03-15 上海朝晖药业有限公司 碘-恩杂鲁胺及其制备方法及其应用
CN117164520B (zh) * 2022-01-28 2025-04-25 南京思聚生物医药有限公司 一种局部作用的雄激素受体拮抗剂及其应用
KR20230170859A (ko) 2022-06-11 2023-12-19 이태영 패스트칫솔
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
EP4374853A1 (en) 2022-11-22 2024-05-29 Lotus Pharmaceutical Co., Ltd. Solid formulation of enzalutamide
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
CN115850186B (zh) * 2023-02-07 2024-04-09 长沙泽达医药科技有限公司 一种乙撑硫脲衍生物的晶型及用途
WO2025125565A1 (en) 2023-12-13 2025-06-19 Krka, D.D., Novo Mesto Tablet comprising enzalutamide
WO2025210510A1 (en) 2024-04-04 2025-10-09 Pfizer Inc. Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
HU193191B (en) * 1982-12-06 1987-08-28 Pfizer Process for preparing spiro-hetero-azolones
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
EP0748220A4 (en) † 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
FR2741342B1 (fr) * 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
DE69938005T2 (de) 1998-09-22 2009-01-15 Astellas Pharma Inc. Cyanophenyl-derivate
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
US20060025589A1 (en) 2002-10-01 2006-02-02 Jean Binet 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US20050005529A1 (en) 2003-07-10 2005-01-13 David Brault Lighting system for a greenhouse
AU2005232526B2 (en) * 2004-02-24 2011-06-23 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
JP4989227B2 (ja) * 2004-09-09 2012-08-01 中外製薬株式会社 新規イミダゾリジン誘導体およびその用途
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR102481886B1 (ko) 2005-05-13 2022-12-28 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물

Also Published As

Publication number Publication date
CY1112798T1 (el) 2015-11-04
JP2012236843A (ja) 2012-12-06
KR101431407B1 (ko) 2014-08-18
WO2006124118A1 (en) 2006-11-23
NZ591119A (en) 2012-08-31
KR20240148945A (ko) 2024-10-11
JP2019218352A (ja) 2019-12-26
KR101332924B1 (ko) 2013-11-26
DK2444085T3 (en) 2015-04-27
HK1169321A1 (en) 2013-01-25
PT2444085E (pt) 2015-06-11
RU2017142159A (ru) 2019-06-05
KR101579701B1 (ko) 2015-12-22
EP1893196A1 (en) 2008-03-05
NO2017019I2 (no) 2017-05-04
ATE541571T1 (de) 2012-02-15
SI1893196T2 (sl) 2015-10-30
CN120682155A (zh) 2025-09-23
JP2022101657A (ja) 2022-07-06
CA2608436C (en) 2015-03-24
NO342490B1 (no) 2018-06-04
AU2006248109B2 (en) 2012-11-15
KR20080014039A (ko) 2008-02-13
ME01992B (me) 2012-10-30
SG10201703816SA (en) 2017-06-29
KR102713358B1 (ko) 2024-10-02
KR20190104244A (ko) 2019-09-06
KR20140041831A (ko) 2014-04-04
JP2021035970A (ja) 2021-03-04
NZ564223A (en) 2011-03-31
NO20180225A1 (no) 2008-02-08
RU2448096C2 (ru) 2012-04-20
JP2016183200A (ja) 2016-10-20
JP5150780B2 (ja) 2013-02-27
EP3970721A1 (en) 2022-03-23
KR20170107585A (ko) 2017-09-25
KR101515335B1 (ko) 2015-04-24
RU2638833C2 (ru) 2017-12-18
ZA201201793B (en) 2015-12-23
MX394667B (es) 2025-03-21
KR102481886B1 (ko) 2022-12-28
JP2011068653A (ja) 2011-04-07
CN105037273B (zh) 2019-04-19
BRPI0610359B8 (pt) 2021-05-25
RU2007146462A (ru) 2009-06-20
NO20076401L (no) 2008-02-08
IL243812A0 (en) 2016-04-21
KR20140141676A (ko) 2014-12-10
EP2444085B1 (en) 2015-03-18
CN102584712A (zh) 2012-07-18
CN116003328A (zh) 2023-04-25
ES2378778T5 (es) 2015-09-25
BRPI0610359A2 (pt) 2010-06-15
CY2013047I1 (el) 2015-11-04
SI2444085T1 (sl) 2015-06-30
EP1893196B1 (en) 2012-01-18
CN110003114B (zh) 2023-01-17
EP1893196B2 (en) 2015-07-29
CN110003114A (zh) 2019-07-12
NZ710355A (en) 2017-01-27
HRP20150437T1 (xx) 2015-06-05
HRP20120323T4 (hr) 2015-10-09
KR20110041580A (ko) 2011-04-21
CN101222922A (zh) 2008-07-16
ES2535179T3 (es) 2015-05-06
PL1893196T3 (pl) 2012-06-29
KR101169832B1 (ko) 2012-07-30
HK1112856A1 (en) 2008-09-19
JP2024153705A (ja) 2024-10-29
JP2025166151A (ja) 2025-11-05
ES2378778T3 (es) 2012-04-17
JP6013535B2 (ja) 2016-10-25
JP2023075313A (ja) 2023-05-30
DK1893196T3 (da) 2012-04-10
RU2448096C3 (ru) 2017-12-11
CY2013047I2 (el) 2015-11-04
EP1893196A4 (en) 2009-03-18
RS52274B (sr) 2012-10-31
KR20210136161A (ko) 2021-11-16
IL187328A0 (en) 2008-04-13
KR20120102140A (ko) 2012-09-17
DK1893196T4 (en) 2015-10-19
JP2008540523A (ja) 2008-11-20
RS53967B1 (sr) 2015-08-31
CN101222922B (zh) 2012-04-18
JP4644737B2 (ja) 2011-03-02
KR101782236B1 (ko) 2017-09-26
HK1217103A1 (zh) 2016-12-23
NO2017019I1 (no) 2017-05-04
HUS1300076I1 (hu) 2013-12-17
RS52274B2 (sr) 2018-05-31
KR102324567B1 (ko) 2021-11-09
BE2013C074I2 (cg-RX-API-DMAC7.html) 2025-09-17
KR20130060369A (ko) 2013-06-07
MX346924B (es) 2017-04-05
IL187328A (en) 2016-02-29
KR20230003445A (ko) 2023-01-05
MX2019015200A (es) 2020-02-05
JP2015098497A (ja) 2015-05-28
JP5138753B2 (ja) 2013-02-06
NO339997B1 (no) 2017-02-27
PL1893196T5 (pl) 2015-12-31
HRP20120323T1 (en) 2012-05-31
IL323480A (en) 2025-11-01
SI1893196T1 (sl) 2012-06-29
IL258880A (en) 2018-06-28
EP2444085A1 (en) 2012-04-25
JP2012211190A (ja) 2012-11-01
KR20150086567A (ko) 2015-07-28
EP2561871A1 (en) 2013-02-27
JP2018100292A (ja) 2018-06-28
KR102020721B1 (ko) 2019-09-10
NO20161996A1 (no) 2008-02-08
PT1893196E (pt) 2012-04-03
KR101332889B1 (ko) 2013-11-26
LU92338I2 (fr) 2015-10-27
AU2006248109A1 (en) 2006-11-23
BRPI0610359B1 (pt) 2020-09-24
ZA200710870B (en) 2012-06-27
CA2608436A1 (en) 2006-11-23
CN105037273A (zh) 2015-11-11
MX2022009759A (es) 2022-09-05
MX2007014132A (es) 2008-04-09
EP3106162A1 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
PL2444085T3 (pl) Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka
SG170809A1 (en) Diarylthiohydantoin compounds
MX2007002675A (es) Antagonistas anti-beta7 humanizados y usos para los mismos.
ATE469895T1 (de) Cgrp-rezeptorantagonisten
MY152068A (en) Bispecific anti-her antibodies
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
TNSN06321A1 (en) Beta-carbolines useful for treating inflammatory disease
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
WO2007033140A3 (en) Prok2 antagonists and methods of use
ZA200705490B (en) Substituted benzimidazoles for treatment of histomoniasis
HK1147475A (en) Diarylhydantoin compounds as androgen receptor modulators
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer